Home > Insider Trading > Filing (0001127602-16-045126)

Filing Details

Accession Number:: 0001127602-16-045126
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-03-04 18:07:54
Reporting Period:: 2016-03-02

Filing Date:: 2016-03-04
Accepted Time:: 2016-03-04 18:07:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1396482	A Robert Bradway	One Amgen Center Drive Thousand Oaks CA 91320-1799	Chairman, Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-03-02	113,175	$0.00	383,102	No	4	A	Direct
Common Stock	Acquisiton	2016-03-02	20,000	$50.44	403,102	No	4	M	Direct
Common Stock	Disposition	2016-03-02	20,000	$146.48	383,102	No	4	S	Direct
Common Stock	Acquisiton	2016-03-02	64,000	$50.44	447,102	No	4	M	Direct
Common Stock	Disposition	2016-03-02	43,799	$148.39	403,303	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nqso (Right to Buy)	Disposition	2016-03-02	20,000	$0.00	20,000	$50.44
Common Stock	Nqso (Right to Buy)	Disposition	2016-03-02	64,000	$0.00	64,000	$50.44

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
64,000	2010-04-28	2016-04-28	No	4	M	Direct
0	2010-04-28	2016-04-28	No	4	M	Direct

Footnotes

The price reported is an average price. The prices ranged from $146.41 to $146.72 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
Open market exercise of 20,000 stock options expiring April 28, 2016 wherein a portion of the cash received as a result of the exercise of these options was used to cover the option exercise price and the remaining balance was remitted in full by the Company to the appropriate California and federal taxing authorities to cover the reporting person's tax liability arising from the reported transactions.
Non-market exercise of 64,000 stock options expiring April 28, 2016 wherein 43,799 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and statutory tax withholding, with the remaining shares delivered to the reporting person.
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,119 RSUs which vest on 4/27/2016; 6,356 RSUs which vest on 1/28/2017; 10,139 RSUs which vest in two installments of 4,994 and 5,145 on 1/31/2017 and 1/31/2018, respectively; and 13,398 shares which vest in two equal installments of 4,421 on 1/30/2017 and 1/30/2018 and one installment of 4,556 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 1,555 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.